Perceived quality of life in patients with psoriasis treated with interleukin 17 and 23 inhibitors.

Autor:	Anguita-Montenegro B; Servicio de Farmacia, Hospital General Universitario de Ciudad Real, Ciudad Real, España. Electronic address: barbara.anguita.94@gmail.com., Areas-Del Águila VL; Servicio de Farmacia, Hospital General Universitario de Ciudad Real, Ciudad Real, España., Palacios-Moya E; Servicio de Farmacia, Hospital General Universitario de Ciudad Real, Ciudad Real, España., García-Arpa M; Servicio Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, España., Sánchez-Caminero MP; Servicio Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, España., Luque-Jiménez M; Servicio de Farmacia, Hospital General Universitario de Ciudad Real, Ciudad Real, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2024 Sep-Oct; Vol. 48 (5), pp. 204-211. Date of Electronic Publication: 2024 Feb 29.
DOI:	10.1016/j.farma.2024.01.004
Abstrakt:	Objective: To determine the effectiveness in terms of quality of life perceived by adult patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors and to identify associated factors. Method: Cross-sectional observational study including adult patients diagnosed with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors for at least 12 or 16 weeks in follow-up, respectively. Results: Forty-one patients were included: 65% male, median age 54 years (SD=13). The included patients were treated with ixekizumab 35%, guselkumab 25%, secukinumab 17.5%, brodalumab 15% and risankizumab 7.5%. Psoariasis area severity index (PASI) reduction was 94.6% (RIC 76.8-100%), DLQI of 1 (RIC 0-2.75), DLQI ≤ 1, 60%. The most affected health dimensions were symptoms and perceptions (57.5%), activities of daily living (27.5%) and discomfort caused with treatment (17.5%). No association was found between DLQI score < 1 and demographic, comorbidities and treatment-related variables. The median PASI reduction in patients with DLQI<1 was superior to patients with DLQI > 1 (100% vs 90.2%, p=0.025). Conclusions: Patients with moderate/severe plaque psoriasis treated with interleukin 17 or 23 inhibitors achieve adequate therapeutic targets achieving the target set according to clinical practice guideline recommendations (score ≤1 on the DLQI questionnaire and 90-100% reduction in the PASI index) and in accordance with the results of recent meta-analyses and real-life studies. A greater reduction of the PASI index is observed in the group reaching the quality of life target, there being the possibility of using patient-reported outcomes in the evaluation of treatment effectiveness. (Copyright © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu